CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA This article explores the key points surrounding this topic, offering insights into recent developments and their implications. SHANGHAI, March 2, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to satricabtagene autoleucel (“satri-cel”, CT041) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction cancer (G/GEJ) in patients who have failed at least two prior lines of therapy.
With growing interest and ongoing research, this topic continues to shape our understanding and approach. The findings highlighted in this article contribute to the broader conversation and open doors for future studies and practical applications. Click for More Details
